P1186: RETROSPECTIVE STUDY: ZANUBRUTINIB COMBINED WITH R-CHOP OR R-CHOP REGIMEN IN THE TREATMENT OF UNTREATED NON-GERMINAL CENTER B-CELL SUBTYPE DIFFUSE LARGE B-CELL LYMPHOMA WITH...

por Caixia, LI, Geng, Hongzhi, Zong, Xiangping, Zhang, Ying, Jia, Sixun, Jiaqi, LI, Zhou, Jin, Wu, Depei
Publicado 2023

Cytopenia after chimeric antigen receptor T cell immunotherapy in relapsed or refractory lymphoma

por Zhou, Jin, Zhang, Ying, Shan, Meng, Zong, Xiangping, Geng, Hongzhi, Li, Jiaqi, Chen, Guanghua, Yu, Lei, Xu, Yang, Li, Caixia, Wu, Depei
Publicado 2022

Efficacy and safety of zanubrutinib plus R-CHOP in treatment of non-GCB DLBCL with extranodal involvement

por Geng, Hongzhi, Jia, Sixun, Zhang, Ying, Li, Jiaqi, Yang, Qin, Zeng, Liangyu, Zong, Xiangping, Lu, Yutong, Lu, Shuangzhu, Zhou, Jin, Li, Caixia, Wu, Depei
Publicado 2023

PB2289: PRELIMINARY DATA FROM A FIRST-IN HUMAN PHASE II STUDY OF SEQUENTIAL USE OF SELINEXOR AND CD19 CHIMERIC ANTIGEN RECEPTOR MODIFIED T-CELL THERAPY (CART19) IN PATIENTS WITH RE...

por Zhang, Ying, Zong, Xiangping, LI, Jiaqi, Jia, Sixun, Geng, Hongzhi, Zeng, Liangyu, Yang, Qin, Cai, Wenzhi, Liu, Shuangzhu, Lu, Yutong, Yu, Lei, LI, Caixia, Wu, Depei
Publicado 2023

Anti-PD-1 Therapy Enhances the Efficacy of CD30-Directed Chimeric Antigen Receptor T Cell Therapy in Patients With Relapsed/Refractory CD30+ Lymphoma

por Sang, Wei, Wang, Xiangmin, Geng, Hongzhi, Li, Tianci, Li, Dashan, Zhang, Bingpei, Zhou, Yi, Song, Xuguang, Sun, Cai, Yan, Dongmei, Li, Depeng, Li, Zhenyu, Li, Caixia, Xu, Kailin
Publicado 2022

A Prospective Investigation of Bispecific CD19/22 CAR T Cell Therapy in Patients With Relapsed or Refractory B Cell Non-Hodgkin Lymphoma

por Zhang, Ying, Li, Jiaqi, Lou, Xiaoyan, Chen, Xiaochen, Yu, Zhou, Kang, Liqing, Chen, Jia, Zhou, Jin, Zong, Xiangping, Yang, Zhen, Li, Minghao, Xu, Nan, Jia, Sixun, Geng, Hongzhi, Chen, Guanghua, Dai, Haiping, Tang, Xiaowen, Yu, Lei, Wu, Depei, Li, Caixia
Publicado 2021